Vertigo medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 20: Line 20:
|
|
*
*
|-
!Benign positional paroxysmal vertigo
!Benign positional paroxysmal vertigo
|
|
Line 31: Line 32:
|
|
*
*
|-
![[Cholesteatoma]]
![[Cholesteatoma]]
|
|
*
*
|-
![[Otosclerosis]]
![[Otosclerosis]]
|
|
*
*
|-
![[Perilymphatic fistula]]
![[Perilymphatic fistula]]
|
|
Line 43: Line 47:
! colspan="2" |Treating Central Vertigo
! colspan="2" |Treating Central Vertigo
|-
|-
![[Orbit (anatomy)|Orbital]] and locoregional retinoblastoma
![[Brainstem]] [[Stroke]]
|
|
* [[Chemotherapy]]
*  
* [[Radiation therapy]]
|-
|-
![[CNS disease]]
![[Vestibular]] [[Migraine]]
|
|
*[[Systemic]] [[chemotherapy]] and [[CNS]]-directed [[therapy]]
*
*[[Systemic]] [[chemotherapy]] followed by myeloablative [[chemotherapy]] and [[stem cell]] rescue
|-
|-
!Trilateral retinoblastoma
![[Multiple Sclerosis]]
|
|
*[[Systemic]] [[chemotherapy]] followed by [[surgery]] and myeloablative [[chemotherapy]] with [[stem cell]] rescue
*
*[[Systemic]] [[chemotherapy]] followed by [[surgery]] and [[radiation therapy]]
|-
|-
![[Extracranial]] [[metastatic]] retinoblastoma
![[Cerebellar]] [[tumors]]
|
|
*[[Systemic]] [[chemotherapy]] followed by myeloablative [[chemotherapy]] with [[stem cell]] rescue and [[radiation therapy]]
*
|-
|-
!Progressive or recurrent extraocular retinoblastoma
![[Lateral medullary syndrome]]
|
|
*[[Systemic]] [[chemotherapy]] and [[radiation therapy]] for [[orbital disease]]
*
*[[Systemic]] [[chemotherapy]] followed by myeloablative [[chemotherapy]] with [[stem cell]] rescue, and [[radiation therapy]] for extra-[[Orbital Disease|orbital]] [[disease]]
|}
|}

Revision as of 16:51, 28 December 2020

Vertigo Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Vertigo from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Vertigo medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Vertigo medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Vertigo medical therapy

CDC on Vertigo medical therapy

Vertigo medical therapy in the news

Blogs on Vertigo medical therapy

Directions to Hospitals Treating Vertigo

Risk calculators and risk factors for Vertigo medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Zehra Malik, M.B.B.S[2]

Treating Peripheral Vertigo
Ménière’s disease
or gentamicin[2] injections in middle ear. 
Acoustic neuroma
Benign positional paroxysmal vertigo
Acute labyrinthitis
Acute vestibular neuritis
Cholesteatoma
Otosclerosis
Perilymphatic fistula
Treating Central Vertigo
Brainstem Stroke
Vestibular Migraine
Multiple Sclerosis
Cerebellar tumors
Lateral medullary syndrome
  1. Phillips, John S; Westerberg, Brian (2011). "Intratympanic steroids for Ménière's disease or syndrome". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD008514.pub2. ISSN 1465-1858.
  2. Postema, Rolf J.; Kingma, Charlotte M.; Wit, Hero P.; Albers, Frans W.J.; Van Der Laan, Bernard F.A.M. (2009). "Intratympanic gentamicin therapy for control of vertigo in unilateral Menière's disease: a prospective, double-blind, randomized, placebo-controlled trial". Acta Oto-Laryngologica. 128 (8): 876–880. doi:10.1080/00016480701762458. ISSN 0001-6489.
  3. Syed, I.; Aldren, C. (2012). "Meniere's disease: an evidence based approach to assessment and management". International Journal of Clinical Practice. 66 (2): 166–170. doi:10.1111/j.1742-1241.2011.02842.x. ISSN 1368-5031.